Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
Last trade$0.6963
Day change+$0.0267 (+3.99%)
Day range$0.655 – $0.702
Volume633,011
Market cap$40M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$40.44M
Price / earnings
—
Price / book
1.15×
Price / sales
—
EV / sales
—
EV / EBITDA
0.03×
Profitability
Earnings per share
-$0.32
Return on assets
-44.09%
Return on equity
-54.3%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
5.45×
Quick ratio
5.45×
Cash ratio
5.2×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$19.15M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ALDX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$2.3M
$2.37M
$1.14M
$2.36M
$2.57M
$1.66M
$3M
$1.95M
Research and development
$1.84M
$3.48M
$2.41M
$4.3M
$5.43M
$8.51M
$7.42M
$14.63M
Total operating expenses
$4.14M
$5.85M
$3.55M
$6.67M
$8M
$10.17M
$10.43M
$16.58M
Operating income
-$4.14M
-$5.85M
-$3.55M
-$6.67M
-$8M
-$10.17M
-$10.43M
-$16.58M
Interest expense
-$438
-$23
-$468.68K
-$475.26K
-$475.9K
-$470.62K
-$483.53K
-$470.86K
Income before taxes
-$3.76M
-$5.45M
-$3.45M
-$6.46M
-$7.69M
-$9.77M
-$9.93M
-$15.81M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$3.76M
-$5.45M
-$3.45M
-$6.46M
-$7.69M
-$9.77M
-$9.93M
-$15.81M
Net income attributable to common shareholders
-$3.76M
-$5.45M
-$3.45M
-$6.46M
-$7.69M
-$9.77M
-$9.93M
-$15.81M
EBITDA
-$3.98M
-$5.78M
-$3.48M
-$6.6M
-$7.94M
-$10.11M
-$10.37M
-$16.51M
Basic earnings per share
-$0.06
-$0.09
-$0.06
-$0.11
-$0.13
-$0.16
-$0.17
-$0.27
Diluted earnings per share
-$0.06
-$0.09
-$0.06
-$0.11
-$0.13
-$0.16
-$0.17
-$0.27
Recent news
Company coverage with links to the original publishers.
Ultragenyx Pharmaceutical agreed to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $203 million following FDA approval of Fayuvi, a gene therapy for mucopolysaccharidosis type IIIA. This marks the company's second PRV sale in one week, with the previous Genglycos voucher sale generating $210 million. Both transactions provide non-dilutive funding to support pipeline development and profitability goals.
Alto Neuroscience (ANRO), a clinical-stage biopharmaceutical company, is advancing its precision psychiatry pipeline with three key candidates. ALTO-207 for treatment-resistant depression showed encouraging phase IIa results, with phase IIb results expected in H2 2027. ALTO-300 and ALTO-100 are in phase IIb studies with top-line results expected in H1 2027 and mid-2027 respectively. ALTO-101 for schizophrenia-related cognitive impairment failed its primary endpoint but showed some secondary signals. Year-to-date, ANRO shares have risen 24.1%, outperforming the biotech industry's 2.9% growth.
Syndax Pharmaceuticals (SNDX) shares fell 15.7% after its phase II MAXPIRe study of axatilimab failed to meet the primary endpoint in idiopathic pulmonary fibrosis (IPF) treatment. The drug showed no benefit in slowing FVC decline, though it maintained a favorable safety profile. The company is discontinuing IPF development but will continue pursuing axatilimab in chronic graft-versus-host disease (cGVHD) with results expected in 2026 and 2028.
Prime Medicine (PRME) has achieved significant regulatory and clinical progress, receiving FDA clearance for PM647 targeting alpha-1 antitrypsin deficiency and dosing the first patient in a phase I/II trial of PM577a for Wilson disease. The stock has gained 26% over the past month, outperforming the biotech industry's 2.8% decline, driven by these encouraging developments in its Prime Editing platform for genetic disease treatments.
PMV Pharmaceuticals (PMVP) has gained nearly 19% in three months following encouraging clinical data for its lead drug rezatapopt, which achieved a 46% response rate in ovarian cancer patients. The company plans to submit an NDA in Q1 2027 and raised $50.8 million through a public offering to fund operations into Q1 2028.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.